4-(1-Amino-ethyl)-1-ethyl-piperidin | 21168-70-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(1-Amino-ethyl)-1-ethyl-piperidin
• 英文别名: 1-(1-ethyl-piperidin-4-yl)-ethylamine；1-(1-Ethyl-4-piperidinyl)ethanamine；1-(1-ethylpiperidin-4-yl)ethanamine
• CAS: 21168-70-7
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: AAVFYQULCROZCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Substituted Triazines for Malaria Treatment and Chemoprophylaxis
  申请人：The United States of America, as represented by the Secretary of the Army, on behalf of the Walter

  公开号：US20150210652A1

  公开（公告）日：2015-07-30

  Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.

  本文披露了三嗪化合物及其制备和使用方法，用于治疗疟疾，提供化学预防，以及治疗或抑制一种或多种疟原虫感染。
• Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis
  申请人：Walter Reed Army Inst. of Research The USA, as represented by the Sec. of the Army, on behalf of the

  公开号：US20160213675A1

  公开（公告）日：2016-07-28

  Disclosed herein are triazine compounds and methods of making and using thereof to treat malaria, provide chemoprophylaxis, and/or treat or inhibit infection by one or more Plasmodium spp.

  本文披露了三嗪化合物及其制备和使用方法，用于治疗疟疾，提供化学预防，并/或治疗或抑制一种或多种疟原虫感染。
• TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITOR
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3858832A1

  公开（公告）日：2021-08-04

  Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

  公开了一种三氟甲基取代的磺酰胺类 BCL-2 选择性抑制剂，特别是公开了一种式 I 的化合物、其立体异构体或药学上可接受的盐、其制备方法及其药物组合物。还公开了所述化合物及其药物组合物治疗抗凋亡 BCL-2 相关疾病（如癌症）的用途。
• [EN] CDK INHIBITOR AND APPLICATION THEREOF<br/>[FR] INHIBITEUR DE CDK ET SON UTILISATION<br/>[ZH] 一种CDK激酶抑制剂及其应用
  申请人：ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD

  公开号：WO2020207260A1

  公开（公告）日：2020-10-15

  涉及一种通式为Ⅰ的化合物，或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物，及其含有通式为Ⅰ的化合物的组合物，以及通式为Ⅰ的化合物，或其药学上可接受的盐、立体异构体、酯、前药、溶剂化物和氘代化合物在制备治疗一种或多种细胞周期蛋白依赖激酶相关的疾病的药物中的应用。
• TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS
  申请人：The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research

  公开号：EP2970153B1

  公开（公告）日：2018-02-21